/GMAB
Genmab A/S
GMAB • NASDAQGMAB • NASDAQ • Healthcare
$28.18+1.88%+0.52
$28.18+1.88%(+0.52)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
100Bullish
Risk
90Low Risk
Momentum
38Negative
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
91.7%▼3.7pp
Revenue after COGS
Operating
33.6%▲2.5pp
After operating expenses
Net
25.9%▼10.6pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
19.8
Price vs earnings
EV/EBITDA
17.3
Enterprise value
FCF Yield
6.0%
Cash generation
Earnings Yield
5.0%
Inverse of P/E
Capital Efficiency
11
GoAI Quality ScoreFair
ROEReturn on Equity
16.5%Strong
ROAReturn on Assets
7.5%Strong
ROICReturn on Invested Capital
8.5%Fair
Financial Health
Current RatioHealthy
2.02
Short-term solvency (>1.5)
Net Debt / EBITDAManageable
2.90x
Debt repayment capacity (<3x)
Income QualityStrong
1.23
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $23.73B | $21.53B | $16.47B | $14.51B | $8.42B |
| Gross Profit | $21.76B | $20.54B | $16.25B | $14.51B | $8.42B |
| Gross Margin | 91.7% | 95.4% | 98.6% | 100.0% | 100.0% |
| Operating Income | $7.97B | $6.70B | $5.32B | $6.27B | $2.95B |
| Net Income | $6.14B | $7.84B | $4.35B | $5.45B | $2.96B |
| Net Margin | 25.9% | 36.4% | 26.4% | 37.6% | 35.1% |
| EPS | $9.86 | $12.14 | $6.60 | $8.34 | $4.52 |
Average Price Target
$40.50▲ 43.7% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Genmab A/S, the average price target is $40.50, with a high forecast of $48.00 and a low forecast of $34.00. The average price target represents a 43.7% increase from the current price of $28.18.
Highest
$48.00
Average
$40.50
Lowest
$34.00
Rating Distribution
Strong Buy
0
0%
Buy
12
71%
Hold
4
24%
Sell
1
6%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Guggenheim● Maintain
Buy
2026-02-23HC Wainwright & Co.● Maintain
Buy
2026-02-18HC Wainwright & Co.● Maintain
Buy
2026-01-28HC Wainwright & Co.● Maintain
Buy
2026-01-20HC Wainwright & Co.● Maintain
Buy
2025-11-10Truist Securities● Maintain
Buy
2025-11-07HC Wainwright & Co.● Maintain
Buy
2025-10-15HC Wainwright & Co.● Maintain
Buy
2025-10-02Guggenheim▲ Upgrade
Neutral→Buy
2025-09-24Guggenheim▲ Upgrade
Neutral→Buy
2025-09-23Earnings History & Surprises
BEAT RATE
33%
Last 18 quarters
AVG SURPRISE
-28.2%
EPS vs Estimate
BEATS / MISSES
6/11
1 met exactly
LATEST EPS
$0.05
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
-89.1%
$0.05 vs $0.46
Q4 '25
+35.4%
$0.65 vs $0.48
Q3 '25
+38.5%
$0.54 vs $0.39
Q2 '25
+34.8%
$0.31 vs $0.23
Q1 '25
+103.6%
$0.57 vs $0.28
Q4 '24
-17.1%
$0.29 vs $0.35
Q3 '24
-24.1%
$0.22 vs $0.29
Q2 '24
$0.16 vs $0.16
Q1 '24
+5.9%
$0.36 vs $0.34
Q4 '23
-85.0%
$0.47 vs $3.14
Q3 '23
-86.2%
$0.30 vs $2.18
Q2 '23
-92.3%
$0.05 vs $0.65
No investor questions available.
Latest News
No news available